©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
ATF3 Gene
GENOMIC ORGANIZATION, PROMOTER, AND REGULATION (*)

(Received for publication, August 29, 1995; and in revised form, October 12, 1995)

Guosheng Liang (1) Curt D. Wolfgang (1) Benjamin P. C. Chen (1) Tsu-Hua Chen (2)(§) Tsonwin Hai (1) (2) (3)(¶)

From the  (1)Ohio State Biochemistry Program, (2)Department of Medical Biochemistry, and (3)Neurobiotechnology Center, Ohio State University, Columbus, Ohio 43210

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

ATF3 gene, which encodes a member of the activating transcription factor/cAMP responsive element binding protein (ATF/CREB) family of transcription factors, is induced by many physiological stresses. As a step toward understanding the induction mechanisms, we isolated the human ATF3 gene and analyzed its genome organization and 5`-flanking region. We found that the human ATF3 mRNA is derived from four exons distributed over 15 kilobases. Sequence analysis of the 5`-flanking region revealed a consensus TATA box and a number of transcription factor binding sites including the AP-1, ATF/CRE, NF-kappaB, E2F, and Myc/Max binding sites. As another approach to understanding the mechanisms by which the ATF3 gene is induced by stress signals, we studied the regulation of the ATF3 gene in tissue culture cells by anisomycin, an approach that has been used to study the stress responses in tissue culture cells. We showed that anisomycin at a low concentration activates the ATF3 promoter and stabilizes the ATF3 mRNA. Significantly, co-transfection of DNAs expressing ATF2 and c-Jun activates the ATF3 promoter. A possible mechanism implicating the C-Jun NH(2)-terminal kinase/stress-activated protein kinase (JNK/SAPK) stress-inducible signaling pathway in the induction of the ATF3 gene is discussed.


INTRODUCTION

Transcriptional regulation plays an important role in both differentiation and homeostasis (for reviews see (1) and (2) ). We have been studying the ATF/CREB (^1)family of transcription factors ((3, 4, 5, 6) ; for reviews see (7, 8, 9) ). Members of the ATF/CREB family bind to a consensus DNA sequence (TGACGTCA), have a similar DNA binding domain (the basic region/leucine zipper (bZip) domain), and form selective heterodimers with each other via the leucine zipper region. Although all ATF/CREB proteins share similarity in their bZip domains, subgroups of proteins share additional similarity in other regions. For example, ATF1(5) , CREB(4, 6) , and CREM (3) are similar in regions that contain the phosphorylation sites. Similarly, ATF2/CRE-BP1 ((10) ; also named HB16 in (11) ) and ATFa (12) share similarity in regions outside the bZip domain: the first 100 N-terminal residues and the last 13 C-terminal residues. It is possible that proteins within a given subgroup have closely related functions. Proteins between subgroups, however, are completely different from each other outside the DNA binding domain, indicating that they may interact with different proteins or ligands and have different functions.

Consistent with this idea, ATF1 and CREB have been demonstrated to stimulate transcription in response to cAMP and calcium influx (13, 14, 15, 16) , whereas ATF2/CRE-BP1 has been demonstrated to stimulate transcription in response to viral induction(17, 18, 19) . ATF3, on the other hand, is not an activator; it represses transcription when bound to DNA(20) . However, ATF3 can heterodimerize with Jun proteins, and the ATF3/Jun heterodimers have been demonstrated to activate transcription(21, 22) . Therefore, depending on the cellular context, ATF3 may repress transcription as homodimers or activate transcription as heterodimers.

Recently, we found that the level of ATF3 mRNA greatly increases both in tissue culture cells after serum stimulation (20) and in whole organisms after physiological stresses. (^2)Using rats as a model system, we demonstrated that ATF3 mRNA level increased in mechanically injured liver after partial hepatectomy and in chemically injured liver treated with toxins such as carbon tetrachloride or alcohol. ATF3 was also induced in blood-deprived heart (ischemic heart) after coronary artery ligation and in reperfusion-injured heart after coronary artery ligation coupled with reperfusion. Furthermore, ATF3 was induced in postseizure brain treated with pentylenetetrazole. Significantly, ATF3 was not induced in the suprachiasmatic nuclei in entrained rats receiving light stimulation during their subjective night. One difference between light stimulation and the rest of the treatments is that light stimulation does not elicit cellular injuries, whereas the others do. Therefore, these results suggest a correlation between ATF3 gene expression and cellular injuries.^2

In all types of induction, ATF3 mRNA level greatly increased within 2 h after stimulation. This quick induction of the ATF3 gene by many physiological stressors suggests that ATF3 may play an important role in stress responses. It is not clear, however, how stress signals induce ATF3 gene. As a first step toward understanding the induction mechanisms, we isolated the human ATF3 gene and analyzed its 5`-flanking region. We also studied the regulation of the ATF3 gene in tissue culture cells by anisomycin, an approach that has been used to study the stress responses in tissue culture cells(24, 25, 26, 27) . In this report, we present the genome organization of the ATF3 gene and the sequence analysis of its 5`-flanking region. We also describe the effects of anisomycin on the stability of ATF3 mRNA and the activity of ATF3 promoter. The involvement of the stress-inducible JNK/SAPK signal transduction pathway (for a review see (28) ) in the induction of ATF3 gene is discussed.


MATERIALS AND METHODS

Plasmids

pH2.8k, a pGEM3 derivative, contains the HindIII 2.8-kilobase fragment as shown in Fig. 1. This fragment contains the following regions from the ATF3 gene: the 5`-flanking region (-1850 to +1), the first exon (+1 to +167), and 680 base pairs from the first intron. pATF3-CAT contains the -1850 to +34 region of the ATF3 gene. pE4SM-CAT contains the -330 to +17 region of the adenovirus E4 promoter with an internal deletion from -138 to -65(29) . pCG-ATF2 was described previously(20) .


Figure 1: Structure of the human ATF3 gene. Exons are indicated by boxes and designated as A, B, C, D, and E. EcoRI (R) and HindIII (H) restriction sites are shown. pH2.8k contains the indicated 2.8-kilobase fragment.



Screening of the Genomic Library

Genomic DNA isolated from a human placenta was partially digested with MboI; DNA fragments ranging from 16 to 20 kilobases were isolated by sucrose density gradient and cloned into the -FixII vector (Stratagene). Approximately 10^6 plaques were screened by P-labeled ATF3 cDNA.

Cell Culture, Transfection, and Chloramphenicol Acetyltransferase (CAT) Assay

Cell culture, transfection, and CAT assays were performed as described previously (20) with the following modifications. For comparison of promoter activities, HeLa cells were transfected with 2 µg of the indicated reporter construct in addition to 5 µg of pGEM4 (Promega) carrier DNA by the calcium phosphate method. CAT assays were performed 36 h after transfection. For induction experiments, NIH 3T6 cells were transfected with 2 µg of pATF3-CAT or pG6TI-CAT by Lipofectamine (Life Technologies, Inc.), followed by starvation for 72 h in medium containing 0% serum and induction for 24 h in medium containing 20% fetal bovine serum or in medium containing 0.5% fetal bovine serum and one of the following reagents: 50 ng/ml anisomycin or 50 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA). CAT assays were performed after induction. For co-transfection experiments, HeLa cells were transfected with 2 µg of pATF3-CAT in addition to 5 µg of pCG-ATF2 expressing ATF2, pCMV-Jun expressing c-Jun, or 2.5 µg of each DNA. In the reporter alone control, 5 µg of pCG was added.

Cell Labeling and Immunoprecipitation

Cell labeling and immunoprecipitation were described previously(20) .

In Vitro Transcription

In vitro transcription by crude nuclear extract was carried out as described previously(30) . The CAT-primer, 5`-GCCATTGGGATATATCAACGG-3`, is complementary to the region from +29 to +49 of the CAT mRNA. Nuclear extracts were made from uninduced or induced HeLa cells according to Dignam et al.(31) . Induction was carried out for 2 h in medium containing 50 ng/ml anisomycin.

Northern Blot and Primer Extension

Northern blot and primer extension were carried out as described previously(20) . The primer (5`-CTCGGGCGGCCAGGG-3`) is complementary to the region from +141 to +156 of the ATF3 mRNA. Extended products were resolved on an 8% polyacrylamide sequencing gel, and the sequence ladder was generated from the same primer using pH2.8k as a template.

In Situ Hybridization

5 times 10^5 HeLa cells were grown on Superfrost Plus glass slides (VWR Scientific) and starved in medium containing 0% serum for 48 h. The cells were then incubated with growing medium in the absence or presence of 50 ng/ml anisomycin for 2 h. In situ hybridization was carried out as described previously.^2

Analysis of mRNA Half-life

HeLa cells were induced with 20% fetal bovine serum and 50 ng/ml anisomycin for 2 h, washed with phosphate-buffered saline, and incubated with medium containing 10% fetal bovine serum and 25 µg/ml 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB, Sigma). In one set of plates, 50 ng/ml of anisomycin was also included. Total RNA was isolated at the indicated time points and analyzed by Northern blot using ATF3 or GAPDH cDNA as probe.

DNA Sequencing

Dideoxy sequencing was carried out using the regular method with Taq polymerase (Promega) or the cycle sequencing method (Life Technologies, Inc.).


RESULTS

Isolation and Characterization of the Human ATF3 Gene

An unamplified -FixII genomic library prepared from size-fractionated human placenta DNA was screened using ATF3 cDNA as probe. Two overlapping clones, 16kb-1 and 20kb-2, were further characterized using the N-terminal or C-terminal cDNA as probe; only 16kb-1 contained the 5` end of the gene. The 16kb-1 clone was further mapped, subcloned, and sequenced to identify the mRNA coding region, exon/intron junctions, and the 5`-flanking sequences. Fig. 1shows the restriction maps for EcoRI and HindIII. The positions of the exons were determined by Southern blot analysis using cDNA or oligonucleotides as probes. DNA fragments containing the exons were further characterized by detailed restriction mapping and sequencing. Comparison of the genomic and cDNA sequences with the restriction map suggested that the human ATF3 mRNA is derived from four exons distributed over 15 kilobases, designated as exons A, B, C, and E in Fig. 1. Exon A encodes the 5`-untranslated region. Exon B contains the AUG initiation codon and encodes the N-terminal 80 amino acids. Exon C encodes 36 amino acids, which is mostly the basic region. Exon E encodes 65 amino acids, which is mostly the leucine zipper (ZIP) domain; it also encodes the 3`-untranslated region. This organization indicates that exons B, C, and E each encode a functional domain, consistent with the modular nature of many exons. Fig. 2summarizes the exon organization, and Table 1shows the sequences around the exon/intron junctions.


Figure 2: Exon organization of ATF3 and ATF3DeltaZip. Schematic representations of the mRNAs and proteins for ATF3 and ATF3DeltaZip are shown. Exons in mRNAs are indicated by boxes labeled as A, B, C, D, and E. Nucleotide numbers are indicated at the top. Functional domains of proteins are indicated by boxes, with basic region and leucine zipper (ZIP) domains labeled. Amino acid numbers are indicated at the bottom. The codons and amino acids at the border of each domain are indicated.





As reported previously(20) , there is an alternatively spliced isoform of ATF3, ATF3DeltaZip. ATF3DeltaZip contains an additional exon between exons C and E; this additional exon introduces an in-frame termination codon, resulting in a truncated protein lacking the leucine zipper region at the C terminus. In addition, the last three nucleotides (AAA) in exon C were spliced out in this isoform, resulting in a glutamine (Q) residue instead of a lysine (K) residue at the end of the corresponding domain. The splicing event resulting in ATF3DeltaZip was shown previously(20) ; the exon organization of ATF3DeltaZip is shown in Fig. 2.

Identification of the Transcriptional Start Site and Analysis of the 5`-Flanking Sequences

To identify the transcriptional start site of ATF3 gene, we performed primer extension. We incubated HeLa cells with 20% serum to induce ATF3 gene, isolated total RNA, and annealed the RNA to an oligonucleotide complementary to nucleotides +141 to +156 of the ATF3 mRNA and extended the oligonucleotide by reverse transcriptase. As shown in Fig. 3, one major extended product was identified. When compared with the sequencing ladder generated by the same oligonucleotide using pH2.8k which contains the appropriate genomic DNA fragment as a template, the extended product co-migrated with the T residue indicated by a box in Fig. 3. Therefore, the complementary A residue on the mRNA-like strand is indicated as the transcriptional start site in Fig. 4.


Figure 3: Primer extension analysis of ATF3 mRNA. An ATF3-specific primer was annealed to 5 µg of total RNA isolated from serum-induced HeLa cells. The cDNA was extended and resolved on an 8% sequencing gel. The same primer was annealed to pH2.8k, which contains the appropriate genomic fragment, to generate the sequencing ladder. The arrow on the right indicates the transcriptional initiation site; the sequence around this site is indicated on the left.




Figure 4: Nucleotide sequences of the 5`-flanking region of the ATF3 gene. The TATA box and several transcription factor binding sites are boxed and labeled. Due to the limited space, many transcription factor binding sites are not indicated. The arrow marks the transcription start site (+1). The GenBank accession number is U37542.



To analyze the promoter, we sequenced the 5`-flanking region. Fig. 4shows the sequence of the 5`-flanking 1850 nucleotides. Inspection of the 5`-flanking sequence revealed a consensus TATA element around -30 and, interestingly, a consensus ATF/CRE site around -90. We also noticed several other transcription factor binding sites. Among them, two classes of binding sites are especially interesting. One is the inducible site such as the ATF/CRE, AP1, and NF-kappaB sites; the other is the site implicated in cell cycle regulation, such as the Myc/Max and E2F binding sites. It is not clear, however, whether any of these binding sites are functionally important for the promoter activity. The promoter region also contains other transcription factor binding sites, such as the SP1, AP2, AP3, and octamer binding sites, although they are not indicated in Fig. 4.

Promoter Activity of the 5`-Flanking Two-kilobase Region

To find out whether the 5`-flanking region contains promoter activity, we constructed a CAT reporter driven by a fragment containing the 5`-flanking two kilobases (pATF3-CAT), and compared its activity with several that of CAT reporters driven by different sequences: SP1 sites (pG6TI-CAT), adenovirus E4 promoter (pE4SM-CAT), the Rous sarcoma virus long terminal repeat (pRSV-CAT), and the E1B TATA box (pEC). As shown in Fig. 5A, when transfected into HeLa cells, pATF3-CAT was much more active than pEC; it was similar to pE4SM-CAT and 50% active compared with pG6TI-CAT but only 5% active compared with pRSV-CAT. Consistent with this result, pATF3-CAT displayed similar activity as pE4SM-CAT in an in vitro transcription assay but was less active than pG6TI-CAT (Fig. 5B). pRSV-CAT was not included in this assay, because it was not active in vitro.


Figure 5: The ATF3 5` two-kilobase region has promoter activity and can be stimulated by serum and anisomycin. A, in vivo transfection assay. CAT reporters driven by E1B TATA box (pEC), the ATF3 promoter (pATF3-CAT), the adenovirus E4 promoter (pE4SM-CAT), six SP1 sites (pG6TI-CAT), and the Rous sarcoma virus long terminal repeat (pRSV-CAT) were transfected into HeLa cells and assayed for CAT activity. A representative result of three experiments is shown. B, in vitro transcription assay. pATF3-CAT, pE4SM-CAT, and pG6TI-CAT were transcribed in vitro using HeLa cell nuclear extracts. CAT mRNAs were analyzed by primer extension using a CAT-specific primer. C, induction assay. NIH 3T6 cells were transfected with either pATF3-CAT or pG6TI-CAT, starved for 72 h, and then induced as indicated for 24 h. CAT activity was assayed, and an average of four results is shown.



As reported previously(20) , ATF3 gene is induced by serum stimulation in tissue culture cells. We then examined whether pATF3-CAT responds to serum stimulation in tissue culture cells. We transiently transfected pATF3-CAT into NIH 3T6 cells, starved the cells in medium containing 0% serum to arrest the cells in G(0) phase, and induced the cells with 20% serum. We used NIH 3T6 cells instead of HeLa cells, because serum starvation arrests NIH 3T6 cells better than HeLa cells. As shown in Fig. 5C, pATF3-CAT was induced by serum stimulation, whereas pG6TI-CAT was not. In addition, we examined the inducibility of pATF3-CAT by the phorbol ester tetradecanoyl-phorbol acetate, which also induced the endogenous ATF3 gene. (^3)Fig. 5C shows that it slightly induced pATF3-CAT, although the induction was not as high as that of the endogenous ATF3 gene. Taken together, we conclude that the 5`-flanking two-kilobase region contains promoter activity and can confer, as least partly, the responsiveness to several inducing agents.

The Effects of Anisomycin on ATF3 Gene Expression

As described earlier, the ATF3 gene is induced by many physiological stresses.^2 This observation prompted us to ask whether the stress-inducible JNK/SAPK signal transduction pathway (for a review see (28) ) is involved in the induction of ATF3 gene by stress signals. As a first step toward answering this question, we examined the induction of ATF3 gene by anisomycin, because anisomycin at subinhibitory concentrations, concentrations that fail to inhibit protein synthesis, can activate the JNK/SAPK signal transduction pathway(32, 33) . We examined the expression of the endogenous ATF3 gene in tissue culture cells by both Northern blot analysis and in situ hybridization. As shown in Fig. 6, A and B, anisomycin at 50 ng/ml greatly increased the level of ATF3 mRNA. That anisomycin at this concentration did not significantly inhibit protein synthesis was confirmed as follows. We incubated the cells with [S]methionine to radiolabel the newly synthesized proteins in the absence or presence of anisomycin and examined the incorporation of [S]methionine into cellular proteins by an SDS-polyacrylamide gel. As shown in Fig. 6C, at 50 ng/ml (low dose), anisomycin had little effect on the synthesis of total cellular proteins; at 10 µg/ml (high dose), however, anisomycin completely abolished the synthesis. Furthermore, immunoprecipitation using ATF3 antibody indicated that the newly induced ATF3 mRNA was indeed translated to produce ATF3 protein in the presence of 50 ng/ml anisomycin (lanes 5-7). Taken together, this information leads us to conclude that anisomycin at a subinhibitory concentration induces ATF3.


Figure 6: Anisomycin increases the steady-state level of ATF3 mRNA. A, anisomycin at 50 ng/ml increased the ATF3 mRNA level as demonstrated by Northern blot analysis. HeLa cells were starved for 48 h and induced by anisomycin at 50 ng/ml for 2 h. 30 µg of total RNA from untreated or treated cells were analyzed by Northern blot using ATF3 or GAPDH cDNA as probe. B, anisomycin at 50 ng/ml increased the ATF3 mRNA level as demonstrated by in situ hybridization; HeLa cells were starved and then uninduced (left panel) or induced (right panel) as above and assayed by in situ hybridization using ATF3 antisense RNA as probe. Bar, 25 µm. C, anisomycin at 50 ng/ml did not significantly inhibit protein synthesis. Left panel, HeLa cells were incubated with [S]methionine for 2 h in the absence of anisomycin (-) or in the presence of low dose anisomycin (50 ng/ml, L) or high dose anisomycin (10 µg/ml, H). Whole cell extracts (WCE) from approximately the same number of cells were analyzed on an SDS-polyacrylamide gel. Right panel, HeLa cells were incubated with [S]methionine in the absence (-) or presence of low dose anisomycin for 2, 4, or 6 h. ATF3 from approximately the same number of cells was immunoprecipitated by antibody against ATF3 and analyzed on an SDS-polyacrylamide gel. The arrow on the right indicates ATF3.



Because both Northern blot and in situ hybridization detect steady-state mRNA levels, the increase could be due to the increase of mRNA synthesis or the increase of mRNA stability. It is possible that anisomycin treatment stabilizes ATF3 mRNA because the 3`-untranslated region of ATF3 mRNA contains several AUUUA sequences, which have been demonstrated to destabilize mRNA (for reviews see (34) and (35) ). To find out whether anisomycin increases the stability of ATF3 mRNA, we compared the stability of ATF3 mRNA in the absence and presence of anisomycin as follows. We treated HeLa cells with 20% serum and 50 ng/ml of anisomycin for 2 h to increase the steady-state level of ATF3 mRNA. After removal of serum and anisomycin, we added DRB to inhibit further RNA synthesis, allowing the existing RNA to turn over. We then analyzed ATF3 mRNA by Northern blot at various time points to assay for its stability. In one set of plates, we added anisomycin back to determine whether it affects the stability of ATF3 mRNA. As shown in Fig. 7, anisomycin at 50 ng/ml moderately increased the stability of ATF3 mRNA.


Figure 7: Anisomycin moderately increases the stability of ATF3 mRNA. HeLa cells were treated with 20% serum and 50 ng/ml anisomycin for 2 h to increase the steady-state level of ATF3 mRNA. After removal of serum and anisomycin, DRB was included in the medium at a concentration of 25 µg/ml to inhibit RNA synthesis, allowing the existing RNA to decay. No anisomycin (- Anisomycin, lanes 2-6) or 50 ng/ml of anisomycin (+ Anisomycin, lanes 8-12) was included in addition to DRB to examine the effects of anisomycin on ATF3 mRNA stability. Total RNA was isolated at the indicated times and analyzed (30 µg/lane) by Northern blot using ATF3 or GAPDH cDNA as probe. RNAs from the uninduced cells were also analyzed (lanes 1 and 7).



To find out whether anisomycin increases the activity of ATF3 promoter, we examined pATF3-CAT in the absence and presence of anisomycin. We transiently transfected pATF3-CAT into NIH 3T6 cells, starved the cells for 72 h, and induced them for 24 h in medium containing 50 ng/ml anisomycin. As shown in Fig. 5C, pATF3-CAT was more active in the presence of anisomycin than in the absence of anisomycin. A control reporter, pG6TI-CAT, was not activated by anisomycin. We note that pG6TI-CAT was less active than pATF3-CAT in NIH 3T6 cells (Fig. 5C) but was more active than pATF3-CAT in HeLa cells (Fig. 5A). This discrepancy was probably due to the differences between these two cell lines. The observation that pATF3-CAT can be induced by anisomycin was recapitulated by an in vitro transcription assay; nuclear extracts made from anisomycin-treated HeLa cells transcribed the ATF3 promoter at a higher activity than nuclear extracts from untreated HeLa cells (Fig. 8). These two extracts, however, showed no difference in transcribing the control promoter composed of SP1 sites (Fig. 8). These results suggest that the increase of steady-state ATF3 mRNA level in the presence of anisomycin was, at least partly, due to an increase of the ATF3 promoter activity.


Figure 8: Anisomycin treatment increases the ATF3 promoter activity in an in vitro transcription assay. Nuclear extracts from HeLa cells or anisomycin-treated HeLa cells were used to transcribe pATF3-CAT and pG6TI-CAT in vitro. CAT mRNAs were analyzed by primer extension using a CAT-specific primer. A representative result of three experiments is shown.



As described earlier, anisomycin activates the JNK/SAPK signal transduction pathway(32, 33) . Two transcription factors, ATF2 and c-Jun, have been demonstrated to be phosphorylated and activated by this pathway(24, 25, 26, 28, 36, 37, 38, 39) . They in turn regulate target promoters, presumably by binding to the ATF/CRE- or AP-1-related sites. The observations that the ATF3 promoter is activated by anisomycin and that it contains the ATF/CRE and AP-1 sites prompted us to ask whether the ATF3 promoter can be regulated by ATF2 or c-Jun. We transfected pATF3-CAT with DNAs expressing ATF2 or c-Jun into HeLa cells. As shown in Fig. 9, ATF2 by itself did not activate the pATF3-CAT reporter; c-Jun, on the other hand, activated the reporter severalfold. Interestingly, co-transfection of DNAs expressing ATF2 and c-Jun greatly increased the CAT activity. Because the ATF3 promoter contains potential binding sites for ATF2 and c-Jun (ATF and AP-1 sites), our result is consistent with the notion that ATF2 and c-Jun act cooperatively on the ATF3 promoter to activate transcription.


Figure 9: Co-expressing of ATF2 and c-Jun activates the ATF3 promoter. pATF3-CAT was transfected into HeLa cells in the presence of pCG-ATF2 expressing ATF2, or pCMV-Jun expressing c-Jun or pCG-ATF2 plus pCMV-Jun. In the reporter alone control, pATF3-CAT was transfected with pCG, which carries the CMV promoter to make sure that each transfection mix contained the same amount of promoter. CAT activity was assayed, and a representative result of five experiments is shown.




DISCUSSION

Genome Organization of the Human ATF3 Gene

In this report, we describe the genome organization of the human ATF3 gene. We also describe the exon/intron junctions of two alternatively spliced isoforms: ATF3 and ATF3DeltaZip. However, the physiological relevance of these isoforms is not clear at present. Other ATF/CREB family transcription factors have also been demonstrated to have alternatively spliced isoforms. Some examples are CREM (for a review, see (40) ), CREB ((41, 42, 43) ; for a review see (9) ), ATF2(44) , and ATFa(12, 45) . In light of the large and complex genome organization of both CREM and CREB genes, it is possible that the small, 15-kilobase genome region of the human ATF3 gene described in this report represents only a portion of the gene. We are currently further characterizing the ATF3 genome to clarify this point.

The 5`-Flanking Region of the ATF3 Gene

Analysis of the 5`-flanking 1.8-kilobase region revealed various transcription factor binding sites. Two groups of binding sites are of special interest: the inducible sites and the sites implicated in cell cycle regulation. The inducible sites include the ATF/CRE, AP1, and NF-kappaB sites. Because these sites have been demonstrated to be induced by signals such as cAMP, calcium influx, UV irradiation, and cytokines (for reviews see (9) and (46) -52), their presence is consistent with our observation that ATF3 gene is induced by many stimulations.^2 Their presence also supports the observation described in this report that the induction is, at least partly, due to the activation of the ATF3 promoter. In addition, the presence of the ATF/CRE consensus sequence in the ATF3 promoter suggests that the ATF3 gene may be regulated by the ATF/CREB family of transcription factors. The observation that co-expression of ATF2 and Jun activates the ATF3 promoter is consistent with this notion. The presence in the ATF3 promoter of the Myc/Max and E2F sites, sites implicated in cell cycle regulation, implies that the expression of ATF3 gene may also be regulated in an cell cycle-dependent manner. We are currently pursuing this possibility.

The Effects of Anisomycin on the Stability of ATF3 mRNA

As shown in Fig. 7, 50 ng/ml of anisomycin moderately increased the stability of ATF3 mRNA. In this context, it is important to point out that a previous report demonstrated that, in C3H 10T1/2 cells, the half-life of c-fos and c-jun mRNA was 15 and 30 min, respectively, in the presence of subinhibitory concentrations of anisomycin, whereas their half-lives were more than 6 h in the presence of inhibitory concentrations of anisomycin(23) . However, not available were the half-lives of these mRNAs in the absence of anisomycin in C3H 10T1/2 cells. Consequently, it is not clear whether these mRNAs are more stable in the presence of subinhibitory concentrations of anisomycin than in the absence of anisomycin. Therefore, our observation that a subinhibitory concentration of anisomycin stabilizes the ATF3 mRNA does not necessarily contradict their results.

Regulation of the ATF3 Promoter by Anisomycin

In this report, we demonstrate that anisomycin activates the ATF3 gene in tissue culture cells. Although anisomycin is a protein synthesis inhibitor, this activation is independent of its ability to inhibit protein synthesis, because anisomycin at 50 ng/ml, a concentration that does not significantly affect protein synthesis, can still activate the ATF3 gene. Therefore, anisomycin activates the ATF3 gene, not by its ability to generally inhibit protein synthesis, but by its intrinsic ability to activate certain intracellular machinery. One candidate for such a machinery is the JNK/SAPK signal transduction pathway, because anisomycin has been demonstrated to activate this pathway independent of its ability to block protein synthesis(23, 32, 33) . Therefore, our results indicate a correlation between the activation of the JNK/SAPK pathway and the activation of the ATF3 gene.

The activation of the ATF3 gene by anisomycin is, at least in part, due to the stimulation of the ATF3 promoter, because a CAT reporter driven by the ATF3 promoter can be activated by anisomycin (Fig. 5C). Significantly, the ATF3 promoter can also be activated by the coexpression of ATF2 and c-Jun (Fig. 9). Because these two transcription factors have been demonstrated to be phosphorylated and activated by the JNK/SAPK pathway(24, 25, 26, 28, 36, 37, 38, 39) , our preliminary evidence is consistent with the notion that the JNK/SAPK pathway may be involved in the activation of the ATF3 promoter by anisomycin. This notion is reminiscent of the observation that this pathway mediates the induction of the c-jun gene by genotoxic agents(39) .

We emphasize that although our results are consistent with the notion that the JNK/SAPK signaling pathway may be involved in the induction of ATF3 gene by anisomycin, they do not prove it. We also note that although the anisomycin approach has been used successfully as a model system to study stress responses in tissue culture cells (24, 25, 26, 27) , it is not clear whether the mechanisms by which anisomycin induces ATF3 gene in tissue culture cells are the same as that by which physiological stresses induce ATF3 gene in the whole organisms. Clearly, many more experiments are required to clarify these points.

In summary, we analyzed the genome organization and promoter sequences of the human ATF3 gene. We also studied the regulation of ATF3 gene by anisomycin. These results should aid future studies of the induction of ATF3 gene by stress signals.


FOOTNOTES

*
This work was supported by National Institutes of Health Grant GM46218 (to T. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Current address: Dept. of Biochemistry, University of Illinois, Chicago, IL 60612.

To whom correspondence should be addressed: Dept. of Medical Biochemistry, Ohio State University, 1060 Carmack Rd., Columbus, OH 43210. Tel.: 614-292-2910; Fax: 614-292-5379; hai.2{at}osu.eduosu.edu.

(^1)
The abbreviations used are: ATF, activating transcription factor; CREB, cAMP responsive element binding protein; CAT, chloramphenicol acetyltransferase; DRB, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole; JNK/SAPK, C-Jun NH(2)-terminal kinase/stress-activated protein kinase; CREM, cAMP-responsive element modulator.

(^2)
Chen, B. P. C., Wolfgang, C. D., and Hai, T. (1996) Mol. Cell. Ciol. in press.

(^3)
G. S. Liang, C. D. Wolfgang, B. P. C. Chen, T.-H. Chen, and T. Hai, unpublished results.


ACKNOWLEDGEMENTS

We thank Dr. W. Herr for pCG, Dr. T. Curran for pCMV-Jun, Drs. G. Gill and R. Tjian for pG6TI, Drs. S. Liang and M. Ptashne for pEC, Dr. A.P. Young for pRSV-CAT and the human placenta tissue, Dr. J. Lang for HeLa cells, and Dr. L. Johnson for NIH 3T6 cells.


REFERENCES

  1. De La Brousse, F. C., and McKnight, S. L. (1993) Trends Genet. 9, 151-154 [CrossRef][Medline] [Order article via Infotrieve]
  2. Hill, C. S., and Treisman, R. (1995) Cell 80, 199-211 [Medline] [Order article via Infotrieve]
  3. Foulkes, N. S., Borrelli, E., and Sassone-Corsi, P. (1991) Cell 64, 739-749 [Medline] [Order article via Infotrieve]
  4. Gonzalez, G. A., Yamamoto, K. K., Fischer, W. H., Karr, D., Menzel, P., Biggs, W., III, Vale, W. W., and Montminy, M. R. (1989) Nature 337, 749-752 [CrossRef][Medline] [Order article via Infotrieve]
  5. Hai, T., Liu, F., Coukos, W. J., and Green, M. R. (1989) Genes & Dev. 3, 2083-2090
  6. Hoeffler, J. P., Meyer, T. E., Yun, Y., Jameson, J. L., and Habener, J. F. (1988) Science 242, 1430-1433 [Medline] [Order article via Infotrieve]
  7. Brindle, P. K., and Montminy, M. R. (1992) Current Opin. Genet. Dev. 2, 199-204 [Medline] [Order article via Infotrieve]
  8. Ziff, E. B. (1990) Trends Genet. 6, 69-72 [CrossRef][Medline] [Order article via Infotrieve]
  9. Meyer, T. E., and Habener, J. F. (1993) Endocr. Rev. 14, 269-290 [Medline] [Order article via Infotrieve]
  10. Maekawa, T., Sakura, H., Kanei-Ishii, C., Sudo, T., Yoshimura, T., Fujisawa, J., Yoshida, M., and Ishii, S. (1989) EMBO J. 8, 2023-2028 [Abstract]
  11. Kara, C. J., Liou, H.-C., Ivashkiv, L. B., and Glimcher, L. H. (1990) Mol. Cell. Biol. 10, 1347-1357 [Medline] [Order article via Infotrieve]
  12. Gaire, M., Chatton, B., and Kedinger, C. (1990) Nucleic Acids Res. 18, 3467-3473 [Abstract]
  13. Gonzalez, G. A., and Montminy, M. R. (1989) Cell 59, 675-680 [Medline] [Order article via Infotrieve]
  14. Liu, F., Thompson, M. A., Wagner, S., Greenberg, M. E., and Green, M. R. (1993) J. Biol. Chem. 268, 6714-6720 [Abstract/Free Full Text]
  15. Rehfuss, R. P., Walton, K. M., Loriaux, M. M., and Goodman, R. H. (1991) J. Biol. Chem. 266, 18431-18434 [Abstract/Free Full Text]
  16. Sheng, M., McFadden, G., and Greenberg, M. E. (1990) Neuron 4, 571-582 [Medline] [Order article via Infotrieve]
  17. Liu, F., and Green, M. R. (1990) Cell 61, 1217-1224 [Medline] [Order article via Infotrieve]
  18. Du, W., and Maniatis, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2150-2154 [Abstract]
  19. Du, W., Thanos, D., and Maniatis, T. (1993) Cell 74, 887-898 [Medline] [Order article via Infotrieve]
  20. Chen, B. P. C., Liang, G., Whelan, J., and Hai, T. (1994) J. Biol. Chem. 269, 15819-15826 [Abstract/Free Full Text]
  21. Hsu, J.-C., Bravo, R., and Taub, R. (1992) Mol. Cell. Biol. 12, 4654-4665 [Abstract]
  22. Chu, H.-M., Tan, Y., Kobierski, L. A., Balsam, L. B., and Comb, M. J. (1994) Mol. Endocrinol. 8, 59-68 [Abstract]
  23. Edwards, D. R., and Mahadevan, L. C. (1992) EMBO J. 11, 2415-2424 [Abstract]
  24. Derijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037 [Medline] [Order article via Infotrieve]
  25. Kallunki, T., Su, B., Tsigelny, I., Sluss, H. K., Derijard, B., Moore, G., Davis, R. J., and Karin, M. (1994) Genes & Dev. 8, 2996-3007
  26. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. (1994) Nature 369, 156-160 [CrossRef][Medline] [Order article via Infotrieve]
  27. Sluss, H. K., Barrett, T., Derijard, B., and Davis, R. J. (1994) Mol. Cell. Biol. 14, 8376-8384 [Abstract]
  28. Davis, R. J. (1994) Trends Biochem. Sci. 19, 470-473 [CrossRef][Medline] [Order article via Infotrieve]
  29. Horikoshi, M., Hai, T., Lin, Y.-S., Green, M. R., and Roeder, R. G. (1988) Cell 54, 1033-1042 [Medline] [Order article via Infotrieve]
  30. Hai, T., Horikoshi, M., Roeder, R. G., and Green, M. R. (1988) Cell 54, 1043-1051 [Medline] [Order article via Infotrieve]
  31. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489 [Abstract]
  32. Cano, E., Hazzalin, C. A., and Mahadevan, L. C. (1994) Mol. Cell. Biol. 14, 7352-7362 [Abstract]
  33. Mahadevan, L. C., and Edwards, D. R. (1991) Nature 349, 747-748 [Medline] [Order article via Infotrieve]
  34. Beelman, C. A., and Parker, R. (1995) Cell 81, 179-183 [Medline] [Order article via Infotrieve]
  35. Brawerman, G. (1989) Cell 57, 9-10 [Medline] [Order article via Infotrieve]
  36. Gupta, S., Campbell, D., Derijard, B., and Davis, R. J. (1995) Science 267, 389-393 [Medline] [Order article via Infotrieve]
  37. Derijard, B., Raingeaud, J., Barrett, T., Wu, I.-H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682-685 [Medline] [Order article via Infotrieve]
  38. Livingstone, C., Patel, G., and Jones, N. (1995) EMBO J. 14, 1785-1797 [Abstract]
  39. van Dam, H., Wilhelm, D., Herr, I., Steffen, A., Herrlich, P., and Angel, P. (1995) EMBO J. 14, 1798-1811 [Abstract]
  40. Sassone-Corsi, P. (1994) EMBO J. 13, 4717-4728 [Medline] [Order article via Infotrieve]
  41. Waeber, G., Meyer, T. E., LeSieur, M., Hermann, H. L., Gerard, N., and Habener, J. F. (1991) Mol. Endocrinol. 5, 1418-1430 [Abstract]
  42. Ruppert, S., Cole, T. J., Boshart, M., Schmid, E., and Schütz, G. (1992) EMBO J. 11, 1503-1512 [Abstract]
  43. Yin, J. C. P., Wallach, J. S., Wilder, E. L., Klingensmith, J., Dang, D., Perrimon, N., Zhou, H., Tully, T., and Quinn, W. G. (1995) Mol. Cell. Biol. 15, 5123-5130 [Abstract]
  44. Georgopoulos, K., Morgan, B. A., and Moore, D. D. (1992) Mol. Cell. Biol. 12, 747-757 [Abstract]
  45. Chatton, B., Bocco, J. L., Gaire, M., Hauss, C., Reimund, B., Goetz, J., and Kedinger, C. (1993) Mol. Cell. Biol. 13, 561-570 [Abstract]
  46. Roesler, W. J., Vandenbark, G. R., and Hanson, R. W. (1988) J. Biol. Chem. 263, 9063-9066 [Free Full Text]
  47. Montminy, M. R., Gonzalez, G. A., and Yamamoto, K. K. (1990) Trends. Neurosci. 13, 184-188 [CrossRef][Medline] [Order article via Infotrieve]
  48. Morgan, J. I., and Curran, T. (1991) Annu. Rev. Neurosci. 14, 421-451 [CrossRef][Medline] [Order article via Infotrieve]
  49. Angel, P., and Karin, M. (1991) Biochim. Biophys. Acta 1072, 129-157 [CrossRef][Medline] [Order article via Infotrieve]
  50. Blank, V., Kourilsky, P., and Israël, A. (1992) Trends Biochem. Sci. 17, 135-140 [CrossRef][Medline] [Order article via Infotrieve]
  51. Lenardo, M. J., and Baltimore, D. (1989) Cell 58, 227-229 [Medline] [Order article via Infotrieve]
  52. Thanos, D. T., and Maniatis, T. (1995) Cell 80, 529-532 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.